'This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease.'
Canada has signed agreements with pharmaceutical firms Pfizer and Moderna to supply millions of doses of a COVID-19 vaccine, but the vaccines are still in development while negotiations continue with other potential suppliers. AFP/File/DOMINICK REUTER, Joseph Prezioso
Moderna on Monday announced its experimental vaccine against Covid-19 was shown to be 94.5 percent effective according to early results from a clinical trial with more than 30,000 participants.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.
For more news your way, download The Citizen’s app for iOS and Android.
Download our app
